Identification of genotype-selective anti-tumor agents
View Patent ↗The present invention relate to methods of identifying a genotype-selective agent. In certain embodiments, the invention relates to agents that are selectively toxic to engineered human tumorigenic cells.
1. A method of inducing death in tumor cells, comprising contacting the cells with a compound selected from the group consisting of:
(a) a compound having the following formula:
(b) a compound having the following formula:
2. A method of inducing death in cells in which the RAS pathway is activated, comprising contacting the cells with a compound selected from the group consisting of:
(a) a compound having the following formula:
(b) a compound having the following formula:
3. A method of inducing death in human cells expressing SV40 small T oncoprotein and oncogenic HRAS, comprising contacting the human cells with a compound selected from the group consisting of:
(a) a compound having the following formula:
(b) a compound having the following formula:
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the following formula:
which is selectively toxic to engineered human tumorigenic cells.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the following formula:
which is selectively toxic to engineered human tumorigenic cells.